Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Offers “No Reasonable Expert” Standard For Addressing Fraud Charges

Executive Summary

PhRMA is backing former InterMune CEO W. Scott Harkonen in his appeal of a fraud conviction for making false statements about Actimmune in a press release. The association argues that he expressed a scientific view that is protected from prosecution under the First Amendment.

You may also be interested in...

Pharma Strikes Out At Supreme Court As Three Recent Cert Petitions Fail

Pfizer, Cephalon and former InterMune CEO Scott Harkonen will find no relief from the high court.

Off-Label Prosecutions Hinge On Patient Benefit, Government Attorneys Say

Federal prosecutors say they will not pursue False Claims Act cases in which off-label use is the standard of care and note that the Caronia decision will have little impact on investigations; First Amendment defense fails in Par and Harkonen cases.

When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA

Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts